CETN2, centrin 2, 1069

N. diseases: 20; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0021364
Disease: Male infertility
Male infertility 		0.010 Biomarker phenotype BEFREE Deletion of CETN1 or CETN2 in mice causes male infertility or dysosmia, respectively, without affecting photoreceptor function. 30647131 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 Biomarker phenotype BEFREE Here, we describe two proteins typically associated with microtubules, Centrin 2 (CEN2) and Dynein Light Chain 8a (DLC8a), that are required for efficient host cell invasion. 31206964 2019
CUI: C4721579
Disease: Secondary malignant neoplasm of colon and/or rectum
Secondary malignant neoplasm of colon and/or rectum 		0.010 Biomarker disease BEFREE We examined the copy numbers (CN) of topoisomerase I (TOP1) as well as the ratios of TOP1/CEN-20 and TOP1/CEN-2 as biomarkers for irinotecan efficacy in patients with metastatic colorectal cancer. 28077117 2017
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.010 Biomarker disease BEFREE As amplification of 20q including CEN-20 is common in BC a TOP1/CEN-2 probemix was applied to the validation cohort. 25855483 2015
CUI: C0020255
Disease: Hydrocephalus
Hydrocephalus 		0.010 Biomarker disease BEFREE We generated a germline CETN2 knock-out (KO) mouse presenting with syndromic ciliopathy including dysosmia and hydrocephalus. 24790208 2014
CUI: C0162429
Disease: Malnutrition
Malnutrition 		0.010 Biomarker disease BEFREE Transgenic expression of GFP-CETN2 rescued the Cetn2-deficiency phenotype. 24790208 2014
CUI: C0235287
Disease: Dysosmia
Dysosmia 		0.010 Biomarker disease BEFREE We generated a germline CETN2 knock-out (KO) mouse presenting with syndromic ciliopathy including dysosmia and hydrocephalus. 24790208 2014
CUI: C1328840
Disease: Autoimmune Lymphoproliferative Syndrome
Autoimmune Lymphoproliferative Syndrome 		0.010 Biomarker disease BEFREE Further study indicated that most of the genes in the coexpression network were enriched in ECM-receptor interaction (COL4A2, FN1, and HMMR) and nucleotide excision repair (CETN2 and PCNA) pathways, and that the most significantly related disease was autoimmune lymphoproliferative syndromes. 25299107 2014
CUI: C3888024
Disease: Cacosmia
Cacosmia 		0.010 Biomarker disease BEFREE We generated a germline CETN2 knock-out (KO) mouse presenting with syndromic ciliopathy including dysosmia and hydrocephalus. 24790208 2014
CUI: C4277690
Disease: Ciliopathies
Ciliopathies 		0.010 Biomarker disease BEFREE We generated a germline CETN2 knock-out (KO) mouse presenting with syndromic ciliopathy including dysosmia and hydrocephalus. 24790208 2014
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.010 AlteredExpression disease BEFREE Specifically, centrin 2 and centrin 3 expression levels were classified as moderate or abundant in >97% of samples in the meningioma group, 63% of astrocytomas, >83% of metastatic and pituitary tumors. 23047184 2013
CUI: C0025286
Disease: Meningioma
Meningioma 		0.010 AlteredExpression disease BEFREE Specifically, centrin 2 and centrin 3 expression levels were classified as moderate or abundant in >97% of samples in the meningioma group, 63% of astrocytomas, >83% of metastatic and pituitary tumors. 23047184 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.010 Biomarker group BEFREE Using CEN-2 as a measurement for tumor ploidy levels, we were able to discriminate between different mechanisms of gene gain, which appeared to differ in prognostic impact.TOP1 FISH guidelines have been updated. 23577133 2013
CUI: C0278877
Disease: Adult Meningioma
Adult Meningioma 		0.010 AlteredExpression disease BEFREE Specifically, centrin 2 and centrin 3 expression levels were classified as moderate or abundant in >97% of samples in the meningioma group, 63% of astrocytomas, >83% of metastatic and pituitary tumors. 23047184 2013
CUI: C1762616
Disease: Meningioma, benign, no ICD-O subtype
Meningioma, benign, no ICD-O subtype 		0.010 AlteredExpression disease BEFREE Specifically, centrin 2 and centrin 3 expression levels were classified as moderate or abundant in >97% of samples in the meningioma group, 63% of astrocytomas, >83% of metastatic and pituitary tumors. 23047184 2013
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.010 Biomarker phenotype BEFREE The upregulated genes included MMP-1, -2, SNAI2, CXCL1, 2, 3, PAI-2, while the downregulated genes included cystatin B, TIMP-2, E-cadherin, centrin-2, all of which have been associated with tumor metastasis. 18440302 2008
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.010 Biomarker group BEFREE The upregulated genes included MMP-1, -2, SNAI2, CXCL1, 2, 3, PAI-2, while the downregulated genes included cystatin B, TIMP-2, E-cadherin, centrin-2, all of which have been associated with tumor metastasis. 18440302 2008
CUI: C2752147
Disease: XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C 		0.010 Biomarker disease BEFREE These results reveal a novel vital function for centrin 2 in NER, the potentiation of damage recognition by XPC. 15964821 2005
CUI: C0043346
Disease: Xeroderma Pigmentosum
Xeroderma Pigmentosum 		0.010 Biomarker disease LHGDN Xeroderma pigmentosum group C protein possesses a high affinity binding site to human centrin 2 and calmodulin. 12890685 2003
CUI: C0035335
Disease: Retinoblastoma
Retinoblastoma 		0.010 AlteredExpression disease BEFREE However, only one isoform (centrin 2) is expressed in nondifferentiated, nonciliated retinal cells (retinoblastoma cells), as well as in rat liver, skeletal muscle, and cardiac muscle. 9665797 1998